CVS Health CVS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
CVS Health (CVS) Business Model and Operations Summary
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
Key Insights
CVS Health (CVS) Core Market Data and Business Metrics
Latest Closing Price
$67.98Market Cap
$85.60 BillionPrice-Earnings Ratio
17.21Total Outstanding Shares
1.26 Billion SharesTotal Employees
300,000Dividend
$0.67 Per Share QuarterlyIPO Date
October 1, 1952SIC Description
Retail-drug Stores And Proprietary StoresPrimary Exchange
New York Stock ExchangeHeadquarters
One Cvs Dr., Woonsocket, RI, 02895
Historical Stock Splits
If you bought 1 share of CVS before June 7, 2005, you'd have 2 shares today.
Execution Date | Split Amount |
---|---|
June 7, 2005 | 2-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $-2.54 Billion |
Net Cash Flow From Operating Activities | $4.61 Billion |
Net Cash Flow From Investing Activities, Continuing | $-8.31 Billion |
Net Cash Flow From Operating Activities, Continuing | $4.61 Billion |
Net Cash Flow | $-6.24 Billion |
Net Cash Flow From Financing Activities, Continuing | $-2.54 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Expenses | $150.95 Billion |
Income Tax Expense/Benefit | $1.72 Billion |
Diluted Average Shares | $3.79 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $-6 Million |
Basic Earnings Per Share | $3.95 |
Revenues | $368.91 Billion |
Comprehensive Income
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Comprehensive Income/Loss | $1.21 Billion |
Comprehensive Income/Loss Attributable To Parent | $6.23 Billion |
Comprehensive Income/Loss | $6.22 Billion |
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-6 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $177.32 Billion |
Current Liabilities | $84.63 Billion |
Current Assets | $67.34 Billion |
Equity Attributable To Parent | $74.94 Billion |
Intangible Assets | $27.82 Billion |
Inventory | $17.65 Billion |
Historical Dividends
Current dividend: $0.67 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Mar 20, 2025 | May 1, 2025 | Apr 22, 2025 | $0.665 | Quarterly |
Jan 3, 2025 | Feb 3, 2025 | Jan 23, 2025 | $0.665 | Quarterly |
Sep 19, 2024 | Nov 1, 2024 | Oct 21, 2024 | $0.665 | Quarterly |
Jul 8, 2024 | Aug 1, 2024 | Jul 22, 2024 | $0.665 | Quarterly |
Mar 21, 2024 | May 1, 2024 | Apr 22, 2024 | $0.665 | Quarterly |
Dec 5, 2023 | Feb 1, 2024 | Jan 22, 2024 | $0.665 | Quarterly |
CVS Articles From Financhle
Recent analysis, market insights, and in-depth coverage of CVS from analysts at Financhle
- CVS Health's Q4 FY2024 Earnings Report Unpacked: Triumphs, Trials, and Future ProspectsAnalyze CVS Health's Q4 FY2024 earnings through a lens of strategic nuance and market acumen. Click to understand the interplay of growth, challenges, and forward-thinking in one of healthcare's leading orchestrators.February 12, 2025